eVusheld Assessment reaL wORld Effectiveness in DoD Health System
NCT05569408 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4724
Last updated 2024-09-19
Summary
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population treated in DoD Health system.
Conditions
- COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
Interventions
- DRUG
-
EVUSHELD
Tixagevimab (AZD8895) and cilgavimab (AZD1061)
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-08-10
- Primary Completion
- 2023-12-22
- Completion
- 2023-12-22
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
NCT05375760 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
NCT07215520 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
NCT05541861 ·Status: COMPLETED ·Phase: PHASE1
-
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
NCT06022224 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Phase 2 Study of RSLV-132 in Subjects With Long COVID
NCT04944121 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
NCT05605470 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
NCT04614948 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
NCT05004181 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
NCT06199934 ·Status: COMPLETED
-
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
NCT04952402 ·Status: COMPLETED ·Phase: PHASE4
-
A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses
NCT03362593 ·Status: TERMINATED ·Phase: PHASE1
-
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
NCT05960097 ·Status: COMPLETED ·Phase: PHASE2
-
Sarilumab for Patients With Moderate COVID-19 Disease
NCT04359901 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
NCT04713553 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
NCT04652102 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222
NCT05426343 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults
NCT03473002 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
NCT04908722 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
NCT04955626 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)
NCT04817202 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
NCT05205746 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Responses to COVID-19 Infection or Vaccination
NCT05379478 ·Status: COMPLETED
-
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
NCT05238454 ·Status: UNKNOWN ·Phase: PHASE2
-
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
NCT05405283 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
NCT07266558 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4